BACKGROUND: The limb girdle muscular dystrophies (LGMD) are a heterogeneous group of Mendelian disorders highlighted by weakness of the pelvic and shoulder girdle muscles. Seventeen autosomal loci have been so far identified and genetic tests are mandatory to distinguish among the forms. Mutations at the calpain 3 locus (CAPN3) cause LGMD type 2A. OBJECTIVE: To obtain unbiased information on the consequences of CAPN3 mutations. PATIENTS: 530 subjects with different grades of symptoms and 300 controls. METHODS: High throughput denaturing HPLC analysis of DNA pools. RESULTS: 141 LGMD2A cases were identified, carrying 82 different CAPN3 mutations (45 novel), along with 18 novel polymorphisms/variants. Females had a more favourable course than males. In 94% of the more severely affected patient group, the defect was also discovered in the second allele. This proves the sensitivity of the approach. CAPN3 mutations were found in 35.1% of classical LGMD phenotypes. Mutations were also found in 18.4% of atypical patients and in 12.6% of subjects with high serum creatine kinase levels. CONCLUSIONS: A non-invasive and cost-effective strategy, based on the high throughput denaturing HPLC analysis of DNA pools, was used to obtain unbiased information on the consequences of CAPN3 mutations in the largest genetic study ever undertaken. This broadens the spectrum of LGMD2A phenotypes and sets the carrier frequency at 1:103.
BACKGROUND: The limb girdle muscular dystrophies (LGMD) are a heterogeneous group of Mendelian disorders highlighted by weakness of the pelvic and shoulder girdle muscles. Seventeen autosomal loci have been so far identified and genetic tests are mandatory to distinguish among the forms. Mutations at the calpain 3 locus (CAPN3) cause LGMD type 2A. OBJECTIVE: To obtain unbiased information on the consequences of CAPN3 mutations. PATIENTS: 530 subjects with different grades of symptoms and 300 controls. METHODS: High throughput denaturing HPLC analysis of DNA pools. RESULTS: 141 LGMD2A cases were identified, carrying 82 different CAPN3 mutations (45 novel), along with 18 novel polymorphisms/variants. Females had a more favourable course than males. In 94% of the more severely affected patient group, the defect was also discovered in the second allele. This proves the sensitivity of the approach. CAPN3 mutations were found in 35.1% of classical LGMD phenotypes. Mutations were also found in 18.4% of atypical patients and in 12.6% of subjects with high serum creatine kinase levels. CONCLUSIONS: A non-invasive and cost-effective strategy, based on the high throughput denaturing HPLC analysis of DNA pools, was used to obtain unbiased information on the consequences of CAPN3 mutations in the largest genetic study ever undertaken. This broadens the spectrum of LGMD2A phenotypes and sets the carrier frequency at 1:103.
Authors: I Richard; N Bourg; S Marchand; O Alibert; B Eymard; A J van der Kooi; C E Jackson; C Garcia; J M Burgunder; C Legum; M de Visser; M Fardeau; J S Beckmann Journal: Neuromuscul Disord Date: 1999-12 Impact factor: 4.296
Authors: I Richard; C Roudaut; A Saenz; R Pogue; J E Grimbergen; L V Anderson; C Beley; A M Cobo; C de Diego; B Eymard; P Gallano; H B Ginjaar; A Lasa; C Pollitt; H Topaloglu; J A Urtizberea; M de Visser; A van der Kooi; K Bushby; E Bakker; A Lopez de Munain; M Fardeau; J S Beckmann Journal: Am J Hum Genet Date: 1999-06 Impact factor: 11.025
Authors: M A Hauser; S K Horrigan; P Salmikangas; U M Torian; K D Viles; R Dancel; R W Tim; A Taivainen; L Bartoloni; J M Gilchrist; J M Stajich; P C Gaskell; J R Gilbert; J M Vance; M A Pericak-Vance; O Carpen; C A Westbrook; M C Speer Journal: Hum Mol Genet Date: 2000-09-01 Impact factor: 6.150
Authors: T V Pogoda; I N Krakhmaleva; N A Lipatova; N I Shakhovskaya; S S Shishkin; S A Limborska Journal: Hum Mutat Date: 2000-03 Impact factor: 4.878
Authors: G Bonne; M R Di Barletta; S Varnous; H M Bécane; E H Hammouda; L Merlini; F Muntoni; C R Greenberg; F Gary; J A Urtizberea; D Duboc; M Fardeau; D Toniolo; K Schwartz Journal: Nat Genet Date: 1999-03 Impact factor: 38.330
Authors: E S Moreira; T J Wiltshire; G Faulkner; A Nilforoushan; M Vainzof; O T Suzuki; G Valle; R Reeves; M Zatz; M R Passos-Bueno; D E Jenne Journal: Nat Genet Date: 2000-02 Impact factor: 38.330
Authors: Flávia de Paula; Mariz Vainzof; Maria Rita Passos-Bueno; Rita de Cássia M Pavanello; Sergio Russo Matioli; Louise V B Anderson; Vincenzo Nigro; Mayana Zatz Journal: Eur J Hum Genet Date: 2002-12 Impact factor: 4.246
Authors: C Minetti; F Sotgia; C Bruno; P Scartezzini; P Broda; M Bado; E Masetti; M Mazzocco; A Egeo; M A Donati; D Volonte; F Galbiati; G Cordone; F D Bricarelli; M P Lisanti; F Zara Journal: Nat Genet Date: 1998-04 Impact factor: 38.330
Authors: Sabrina Sacconi; Pilar Camaño; Jessica C de Greef; Richard J L F Lemmers; Leonardo Salviati; Pascal Boileau; Adolfo Lopez de Munain Arregui; Silvère M van der Maarel; Claude Desnuelle Journal: J Med Genet Date: 2011-10-07 Impact factor: 6.318
Authors: Yanchao Huang; Antoine de Morrée; Alexandra van Remoortere; Kate Bushby; Rune R Frants; Johan T den Dunnen; Silvère M van der Maarel Journal: Hum Mol Genet Date: 2008-03-11 Impact factor: 6.150
Authors: Xiomara Q Rosales; Vinod Malik; Amita Sneh; Lei Chen; Sarah Lewis; Janaiah Kota; Julie M Gastier-Foster; Caroline Astbury; Rob Pyatt; Shalini Reshmi; Louise R Rodino-Klapac; K Reed Clark; Jerry R Mendell; Zarife Sahenk Journal: Muscle Nerve Date: 2013-03-29 Impact factor: 3.217
Authors: Sridhar Selvaraj; Neha R Dhoke; James Kiley; Alba Judith Mateos-Aierdi; Sudheer Tungtur; Ricardo Mondragon-Gonzalez; Grace Killeen; Vanessa K P Oliveira; Adolfo López de Munain; Rita C R Perlingeiro Journal: Mol Ther Date: 2019-08-28 Impact factor: 11.454